Focal Epilepsy Clinical Trial
Official title:
Interventional, Randomized, Double-blind, Crossover, Placebo-controlled, Multiple-dose Lu AG06466 Phase 1 B Study in Patients With Focal Epilepsy Using EEG and PSG to Investigate Its Pharmacodynamic Effects on Prolonged Period of Inter- Icterical Spikes, Sleep and Neuroinflammation
Verified date | November 2022 |
Source | H. Lundbeck A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.
Status | Terminated |
Enrollment | 1 |
Est. completion date | April 14, 2022 |
Est. primary completion date | April 14, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Key Inclusion Criteria: - The participant must have had the responsive neurostimulation system (RNSĀ®) System implanted for more than 1 year and medically intractable focal onset epileptic seizures (history of persistent seizures refractory to 2 or more anti-epileptic drugs [AEDs]), with seizures from all foci represented in the implanted RNS electrodes. - The participant is required to have a continuous period of at least 2 months prior to the Screening Visit with constant RNS stimulation settings as well as stable AED (that is, 60 days with no dose adjustments of more than 25%) as determined by medical history and the Patient Data Management System (PDMS). There must be at least 24 recorded long episodes available for review since last change of RNS detection setting. - The participant is required to have approximately 7 or more long episodes per week, as assessed as an average over the last 2 months prior to the Screening Visit. - The participant is required to have a demonstrated history of compliance with RNS scanning and uploading procedure in the past year (less than 20% missing long episode counts on the PDMS). Key Exclusion Criteria: - The participant has the RNS System implanted in other regions than the epileptic foci such as the thalamus. - The participant has a RNS System with anticipated generator change in the coming 6 months. - The participant has a cyclic pattern of long episodes in the last 2 months prior to the Screening Visit which exhibits, in the opinion of the investigator: a period of more than 3 weeks; and peak-to-trough differences of long episodes of more than half the peak level. - The participant has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological (apart from epileptic diagnosis), or psychiatric disease or other major disorder, which in opinion of the investigator may influence efficacy or safety aspects in the study. Other inclusion and exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
United States | Mid-Atlantic Epilepsy and Sleep Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
H. Lundbeck A/S |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of "Long Episodes" (Electrocorticographic [ECoG] Seizures) | "Long Episodes" are abnormal events detected by the neurostimulator that do not return to baseline ECoG activity within a predefined period of time, typically 30 to 60 seconds. These often correspond to ECoG seizures. | Baseline (Day -1) up to Day 29 of each treatment period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02245061 -
Cortical Excitability Assessment Using Paired Pulses
|
N/A | |
Withdrawn |
NCT05481905 -
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
|
Phase 2 | |
Completed |
NCT02208492 -
The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study
|
Phase 4 | |
Recruiting |
NCT04839601 -
RNS System RESPONSE Study
|
N/A | |
Completed |
NCT02898935 -
Improvement of the Accuracy of Spatial Representation of Invasive Exploratory Electrodes in Focal Epilepsy
|
||
Enrolling by invitation |
NCT05748236 -
The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy
|
Phase 4 | |
Terminated |
NCT01724918 -
Lacosamide IV and EEG/EKG (LIVE) Study
|
Phase 2 | |
Completed |
NCT00855738 -
A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
|
Phase 4 | |
Recruiting |
NCT06309966 -
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06210022 -
Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy
|
||
Completed |
NCT01311440 -
Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy
|
N/A | |
Terminated |
NCT03955432 -
Long-term Cardiac Monitoring in Epilepsy
|
N/A | |
Recruiting |
NCT06132893 -
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
|
Phase 2/Phase 3 | |
Recruiting |
NCT05100771 -
Optimized Volumetry in Radiology: Interest in Pediatric Brain MRI in the Exploration of Focal Epilepsy
|
||
Recruiting |
NCT04879433 -
Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy
|
||
Active, not recruiting |
NCT03916848 -
Novel Network Analysis of Intracranial Stereoelectroencephalography
|
N/A | |
Recruiting |
NCT05198882 -
Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy
|
Phase 1 | |
Recruiting |
NCT05981755 -
Breathing Rescue for SUDEP Prevention
|
N/A | |
Recruiting |
NCT03457961 -
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
|
||
Not yet recruiting |
NCT06443463 -
Long-term Safety and Tolerability of BHV-7000
|
Phase 2 |